Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Memoral Sloan Kettering Cancer Center@Phelps
mi
from
Sleepy Hollow, NY
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Memoral Sloan Kettering Cancer Center@Phelps
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Expressive Writing and Adjustment to Metastatic Breast Cancer
Expressive Writing and Adjustment to Metastatic Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Expressive Writing and Adjustment to Metastatic Breast Cancer
Expressive Writing and Adjustment to Metastatic Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated:  10/29/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated: 10/29/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated:  10/29/2015
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated: 10/29/2015
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated:  10/29/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated: 10/29/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated:  10/29/2015
Wilshire Oncology Medical Group, Incorporated - Pomona
mi
from
Pomona, CA
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated: 10/29/2015
Wilshire Oncology Medical Group, Incorporated - Pomona
mi
from
Pomona, CA
Click here to add this to my saved trials
Breast Cancer Risk Biomarkers in Postmenopausal Women
Modulation of Breast Cancer Risk Biomarkers in Postmenopausal Women by High Dose Omega-3 Fatty Acids
Status: Enrolling
Updated:  10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Breast Cancer Risk Biomarkers in Postmenopausal Women
Modulation of Breast Cancer Risk Biomarkers in Postmenopausal Women by High Dose Omega-3 Fatty Acids
Status: Enrolling
Updated: 10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia
Status: Enrolling
Updated:  10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia
Status: Enrolling
Updated: 10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia
Status: Enrolling
Updated:  10/30/2015
U.S. Oncology Research, Inc.
mi
from
Dallas, TX
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia
Status: Enrolling
Updated: 10/30/2015
U.S. Oncology Research, Inc.
mi
from
Dallas, TX
Click here to add this to my saved trials
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer
Status: Enrolling
Updated:  10/30/2015
Lynn Sage Comprehensive Breast Center at Northwestern Memorial Hospital
mi
from
Chicago, IL
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer
Status: Enrolling
Updated: 10/30/2015
Lynn Sage Comprehensive Breast Center at Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer
Status: Enrolling
Updated:  10/30/2015
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
mi
from
Kansas City, KA
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer
Status: Enrolling
Updated: 10/30/2015
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer
Status: Enrolling
Updated:  10/30/2015
Oklahoma University Medical Center
mi
from
Oklahoma City, OK
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer
Status: Enrolling
Updated: 10/30/2015
Oklahoma University Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Protocol for Women at Increased Risk of Developing Breast Cancer
Study of the Effect of Letrozole on Breast Biomarkers of High Risk Postmenopausal Women Receiving Hormone Replacement Therapy
Status: Enrolling
Updated:  10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Protocol for Women at Increased Risk of Developing Breast Cancer
Study of the Effect of Letrozole on Breast Biomarkers of High Risk Postmenopausal Women Receiving Hormone Replacement Therapy
Status: Enrolling
Updated: 10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Protocol for Women at Increased Risk of Developing Breast Cancer
A Double-blinded Phase II Study of the Expression of Ki-67/MIB-1 in Women With Hyperplasia of the Breast Randomized to Receive Daily Celecoxib 400 mg BID or Placebo
Status: Enrolling
Updated:  10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Protocol for Women at Increased Risk of Developing Breast Cancer
A Double-blinded Phase II Study of the Expression of Ki-67/MIB-1 in Women With Hyperplasia of the Breast Randomized to Receive Daily Celecoxib 400 mg BID or Placebo
Status: Enrolling
Updated: 10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
Status: Enrolling
Updated:  10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
Status: Enrolling
Updated: 10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors
Systemic DKK1 During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors
Status: Enrolling
Updated:  11/3/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors
Systemic DKK1 During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors
Status: Enrolling
Updated: 11/3/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Sutter Institute
mi
from
Sacramento, CA
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Sutter Institute
mi
from
Sacramento, CA
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Scripps
mi
from
San Diego, CA
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Scripps
mi
from
San Diego, CA
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Henry Ford Hospital
mi
from
Detroit, MI
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Sinai Grace
mi
from
Detroit, MI
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Sinai Grace
mi
from
Detroit, MI
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Summit Medical Group Breast Center New Jersey
mi
from
Berkeley Heights, NJ
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Summit Medical Group Breast Center New Jersey
mi
from
Berkeley Heights, NJ
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Cleveland Clinic
mi
from
Cleveland, OH
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Mercy Womens Center
mi
from
Oklahoma City, OK
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Mercy Womens Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Rhode Island Hospital
mi
from
Providence, RI
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Avera Research Institute
mi
from
Sioux Falls, SD
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Avera Research Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Mayo Clinic
mi
from
Scottsdale, AZ
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Effect of Cancer Nurse Navigators on Patient Outcomes
Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes
Status: Enrolling
Updated:  11/3/2015
Aurora St. Luke's Hospital
mi
from
Milwaukee, WI
Effect of Cancer Nurse Navigators on Patient Outcomes
Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes
Status: Enrolling
Updated: 11/3/2015
Aurora St. Luke's Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Effect of Cancer Nurse Navigators on Patient Outcomes
Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes
Status: Enrolling
Updated:  11/3/2015
Aurora West Allis
mi
from
West Allis, WI
Effect of Cancer Nurse Navigators on Patient Outcomes
Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes
Status: Enrolling
Updated: 11/3/2015
Aurora West Allis
mi
from
West Allis, WI
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Birmingham, AL
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Altanta, GA
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Altanta, GA
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Boston, MA
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Boston, MA
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
New York, NY
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
New York, NY
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Durham, NC
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Durham, NC
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Columbus, OH
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Philadelphia, PA
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceutical Investigative Site
mi
from
Houston, TX
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceutical Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Cordoba,
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Cordoba,
Click here to add this to my saved trials
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated:  11/5/2015
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated: 11/5/2015
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated:  11/5/2015
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated: 11/5/2015
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated:  11/5/2015
Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated: 11/5/2015
Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Click here to add this to my saved trials
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated:  11/5/2015
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated: 11/5/2015
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25
Status: Enrolling
Updated:  11/5/2015
Emory University Hospital Midtown
mi
from
Atlanta, GA
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25
Status: Enrolling
Updated: 11/5/2015
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25
Status: Enrolling
Updated:  11/5/2015
Grady Memorial Hospital
mi
from
Atlanta, GA
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25
Status: Enrolling
Updated: 11/5/2015
Grady Memorial Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25
Status: Enrolling
Updated:  11/5/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25
Status: Enrolling
Updated: 11/5/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Patient Controlled Tissue Expansion for Breast Reconstruction
AirXpanders Patient Activated Controlled Tissue Expander System for Breast Reconstruction
Status: Enrolling
Updated:  11/5/2015
Baptist Medical Center South
mi
from
Jacksonville, FL
Patient Controlled Tissue Expansion for Breast Reconstruction
AirXpanders Patient Activated Controlled Tissue Expander System for Breast Reconstruction
Status: Enrolling
Updated: 11/5/2015
Baptist Medical Center South
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Patient Controlled Tissue Expansion for Breast Reconstruction
AirXpanders Patient Activated Controlled Tissue Expander System for Breast Reconstruction
Status: Enrolling
Updated:  11/5/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Patient Controlled Tissue Expansion for Breast Reconstruction
AirXpanders Patient Activated Controlled Tissue Expander System for Breast Reconstruction
Status: Enrolling
Updated: 11/5/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Patient Controlled Tissue Expansion for Breast Reconstruction
AirXpanders Patient Activated Controlled Tissue Expander System for Breast Reconstruction
Status: Enrolling
Updated:  11/5/2015
Columbia University
mi
from
New York, NY
Patient Controlled Tissue Expansion for Breast Reconstruction
AirXpanders Patient Activated Controlled Tissue Expander System for Breast Reconstruction
Status: Enrolling
Updated: 11/5/2015
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials